At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERYP Erytech Pharma S.A.
Pre-Market Trading 12-23 05:56:29 EST
0.7800
+0.0000
0.00%
High0.7800
Low0.7800
Vol0.00
Open0.7800
D1 Closing0.7800
Amplitude0.00%
Mkt Cap26.61M
Tradable Cap24.01M
Total Shares34.12M
T/O2.73K
T/O Rate0.00%
Tradable Shares30.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.